Synapse - Shanu Modi

Results (265)

Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC)

Meeting Abstract

Tsurutani, J.; Jacot, W.; Yamashita, T.; Riaz, F.; Yerushalmi, R.; Im, S. A.; Niikura, N.; Halser-Strub, U.; Cortés, J.; Wennstig, A. K.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study

Meeting Abstract

Modi, S.; Jacot, W.; Iwata, H.; Park, Y. H.; Losada, M. J. V.; Li, W.; Tsurutani, J.; Zaman, K.; Ueno, N. T.; Prat, A.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB)-01,-02, and-03

Meeting Abstract

Hurvitz, S. A.; Modi, S.; Li, W.; Park, Y. H.; Chung, W.; Kim, S. B.; Cortés, J.; Yamashita, T.; Pedrini, J.; Im, S. A.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Prognostic implications of HER2 gain in patients with HR+/ HER2-breast cancer (BC) and TNBC after neoadjuvant chemotherapy (NAC)

Meeting Abstract

Ferraro, E.; Chew Minmin, S.; Nemirovsky, D.; Chen, Y.; Barrio, A. V.; Modi, S.; Seidman, A.; Wen, H.; Brogi, E.; Robson, M.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: A matched case analysis

Journal Article

Moss, N. S.; Singh, J. M.; Reiner, A. S.; Drago, J. Z.; Modi, S.; Seidman, A. D.; Chandarlapaty, S.; Ross, D. S.
npj Breast Cancer (2023)

Fulltext@MSK | Save

A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP vs ddAC-THP in high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11)

Meeting Abstract

Harbeck, N.; Boileau, J. F.; Modi, S.; Kelly, C.; Ohno, S.; Wu, J.; Konpa, A.; Herbolsheimer, P.; Safdar, S.; Zhang, Y.; more...
Breast (2023)

Fulltext@MSK | Save

Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04

Meeting Abstract

Modi, S.; Niikura, N.; Yamashita, T.; Jacot, W.; Sohn, J.; Tokunaga, E.; Vidal, M. J.; Park, Y. H.; Lee, K. S.; Chae, Y.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers

Meeting Abstract

Drago, J. Z.; Pareja, F.; Jhaveri, K. L.; Walsh, E. M.; Ku, G. Y.; Maron, S. B.; Janjigian, Y. Y.; Robson, M. E.; Reis-Filho, J. S.; Modi, S.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03

Meeting Abstract

Krop, I. E.; Wildiers, H.; Hurvitz, S. A.; Cortes, J.; Im, S. A.; Iwata, H.; Andre, F.; Saura, C.; Modi, S.; Kim, S. B.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Invasive disease free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab

Meeting Abstract

Chew, S.; Ferraro, E.; Chen, Y.; Barrio, A. V.; Kelly, D. W.; Modi, S.; Seidman, A. D.; Wen, H. Y.; Brogi, E.; Robson, M. E.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save